X
<

Bristol-Myers Squibb after 1Q17: Portfolio Prospects

PART:
1 2 3 4 5 6 7
Part 5
Bristol-Myers Squibb after 1Q17: Portfolio Prospects PART 5 OF 7

Revisiting Bristol-Myers Squibb’s Virology in 1Q17

BMY’s virology portfolio

Bristol-Myers Squibb’s (BMY) virology portfolio includes drugs for chronic virus diseases and infections including Hepatitis B, Hepatitis C, and HIV.

Revisiting Bristol-Myers Squibb’s Virology in 1Q17

Interested in BMY? Don't miss the next report.

Receive e-mail alerts for new research on BMY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Hepatitis C franchise

Daklinza and Sunvepra are the two drugs in BMY’s Hepatitis C franchise. Revenues from these drugs fell to $162 million in 1Q17, as compared to $427 million in 1Q16, following lower sales in both the US and international markets. In US markets, revenues from BMY’s Hepatitis C franchise fell ~84% to $42 million in 1Q17, as compared to $259 million in 1Q16.

These drugs compete with drugs like Harvoni and Sovaldi by Gilead Sciences (GILD), Olysio by Johnson & Johnson (JNJ), and Viekira Pak by AbbVie (ABBV).

HIV franchise

The HIV franchise includes two drugs, Reyataz and Sustiva. In 1Q17, Sustiva revenues declined to $184 million, as compared to $273 million during 1Q16, due to the loss of exclusivity in US markets.

Reyataz revenues fell to $193 million in 1Q17, as compared to $221 million in 1Q16, due to lower sales of the drugs.

Hepatitis B franchise

Baraclude, an oral antiviral, reported a decline in revenues to $282 million 1Q17, as compared to $291 million in 1Q16, due to the generic competition of entecavir tablets from Teva Pharmaceuticals (TEVA).

To divest risk, investors can consider ETFs like the Health Care Select Sector SPDR ETF (XLV), which has ~3.1% of its total assets in Bristol-Myers Squibb. XLV also has 11.5% of its total assets in Johnson & Johnson (JNJ), 3.6% of its total assets in Gilead Sciences (GILD), and 3.7% of its total assets in AbbVie (ABBV).

X

Please select a profession that best describes you: